Geode Capital Management’s SELLAS Life Sciences SLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $72.1M | Buy |
4,884,175
+971,569
| +25% | +$6.71M | ﹤0.01% | 1426 |
|
|
2026
Q1 | $16.6M | Buy |
3,912,606
+835,269
| +27% | +$3.74M | ﹤0.01% | 2096 |
|
|
2025
Q4 | $11.6M | Buy |
3,077,337
+812,953
| +36% | +$1.58M | ﹤0.01% | 2337 |
|
|
2025
Q3 | $3.65M | Buy |
2,264,384
+63,956
| +3% | +$114K | ﹤0.01% | 2935 |
|
|
2025
Q2 | $4.82M | Buy |
2,200,428
+1,379,988
| +168% | +$2.12M | ﹤0.01% | 2752 |
|
|
2025
Q1 | $886K | Buy |
820,440
+86,894
| +12% | +$103K | ﹤0.01% | 3347 |
|
|
2024
Q4 | $763K | Buy |
733,546
+128,355
| +21% | +$147K | ﹤0.01% | 3461 |
|
|
2024
Q3 | $757K | Buy |
605,191
+88,183
| +17% | +$108K | ﹤0.01% | 3454 |
|
|
2024
Q2 | $615K | Buy |
517,008
+243,945
| +89% | +$332K | ﹤0.01% | 3491 |
|
|
2024
Q1 | $276K | Buy |
273,063
+27,460
| +11% | +$23.1K | ﹤0.01% | 3827 |
|
|
2023
Q4 | $260K | Buy |
245,603
+10,000
| +4% | +$10.8K | ﹤0.01% | 3849 |
|
|
2023
Q3 | $387K | Buy |
235,603
+47,537
| +25% | +$75K | ﹤0.01% | 3697 |
|
|
2023
Q2 | $295K | Hold |
188,066
| – | – | ﹤0.01% | 3861 |
|
|
2023
Q1 | $269K | Hold |
188,066
| – | – | ﹤0.01% | 3907 |
|
|
2022
Q4 | $443K | Buy |
188,066
+43,347
| +30% | +$122K | ﹤0.01% | 3717 |
|
|
2022
Q3 | $292K | Hold |
144,719
| – | – | ﹤0.01% | 4005 |
|
|
2022
Q2 | $322K | Buy |
144,719
+7,823
| +6% | +$22.9K | ﹤0.01% | 3994 |
|
|
2022
Q1 | $914K | Buy |
136,896
+3,095
| +2% | +$18.1K | ﹤0.01% | 3659 |
|
|
2021
Q4 | $739K | Hold |
133,801
| – | – | ﹤0.01% | 3855 |
|
|
2021
Q3 | $1.23M | Buy |
133,801
+32,464
| +32% | +$301K | ﹤0.01% | 3580 |
|
|
2021
Q2 | $1.12M | Buy |
101,337
+6,430
| +7% | +$62.8K | ﹤0.01% | 3530 |
|
|
2021
Q1 | $810K | Buy |
94,907
+60,492
| +176% | +$495K | ﹤0.01% | 3644 |
|
|
2020
Q4 | $199K | Sell |
34,415
-26,499
| -44% | -$106K | ﹤0.01% | 3887 |
|
|
2020
Q3 | $161K | Buy |
60,914
+300
| +0.5% | +$822 | ﹤0.01% | 3782 |
|
|
2020
Q2 | $177K | Buy |
60,614
+7,827
| +15% | +$21.2K | ﹤0.01% | 3697 |
|
|
2020
Q1 | $91K | Buy |
52,787
+936
| +2% | +$2.41K | ﹤0.01% | 3800 |
|
|
2019
Q4 | $222K | Buy |
51,851
+28,454
| +122% | +$153K | ﹤0.01% | 3758 |
|
|
2019
Q3 | $141K | Buy |
23,397
+20,921
| +845% | +$154K | ﹤0.01% | 3876 |
|
|
2019
Q2 | $13K | Buy |
2,476
+192
| +8% | +$6.82K | ﹤0.01% | 4182 |
|
|
2019
Q1 | $116K | Hold |
2,284
| – | – | ﹤0.01% | 3862 |
|
|
2018
Q4 | $140K | Buy |
+2,284
| New | +$177K | ﹤0.01% | 3779 |
|
|
2017
Q4 | – | Sell |
-35
| Closed | -$18K | – | 4036 |
|
|
2017
Q3 | $18K | Hold |
35
| – | – | ﹤0.01% | 4018 |
|
|
2017
Q2 | $30K | Sell |
35
-33
| -49% | -$28.7K | ﹤0.01% | 4013 |
|
|
2017
Q1 | $62K | Buy |
68
+21
| +45% | +$34.8K | ﹤0.01% | 3909 |
|
|
2016
Q4 | $136K | Buy |
+47
| New | +$273K | ﹤0.01% | 3718 |
|
Other funds holding SLS
AFM
Geode Capital Management's SLS Position: Q2 2026 in Review
Geode Capital Management increased its SELLAS Life Sciences (SLS) stake by 25% in Q2 2026, buying an estimated $6.71M and bringing the position to 4,884,175 shares worth $72.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1426.
Geode Capital Management first reported a position in SLS in Q4 2016 and has held it in 35 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.
- Geode Capital Management held 4,884,175 shares of SELLAS Life Sciences worth $72.1M as of Q2 2026.
- Geode Capital Management bought 971,569 SELLAS Life Sciences shares in Q2 2026, an estimated $6.71M.
- SELLAS Life Sciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1426 holding.
- Geode Capital Management first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 35 quarters since.
- 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.